57 results about "Pseudorabies" patented technology

The invention relates to the technical field of antibodies, and discloses an antibody for specifically recognizing porcine pseudorabies virus gB (507-734 aa) or an antigen binding fragment thereof and application. The antibody or the antigen binding fragment thereof comprises a heavy chain and a light chain; the antibody or the antigen binding fragment thereof can be used for detecting the existence or the level of the porcine pseudorabies virus gB protein in a sample, and has key significance on optimization of a porcine pseudorabies virus detection method, improvement of diagnosis accuracy and realization of effective prevention and control of epidemic situations.

The invention belongs to the technical field of biology, and particularly relates to a porcine pseudorabies virus gB-gD recombinant fusion protein subunit vaccine as well as a preparation method and application thereof. According to the invention, the PRV gB and gD genes are selected to serially express the gBgD protein to prepare the vaccine, the gB and gD proteins which are respectively expressed are replaced, and the vaccine is high in safety and good in immunogenicity, can effectively prevent the occurrence of a pseudorabies virus virulence enhancement event when being clinically used, provides a powerful space for purification of pseudorabies, and has a wide application prospect.

This invention relates to an anti-swine pseudorabies virus (PRV) preparation and the application of Rehmannia glutinosa polysaccharide in its preparation, belonging to the field of biopharmaceutical technology. This invention provides an anti-swine pseudorabies virus (PRV) preparation comprising Rehmannia glutinosa polysaccharide. It also provides the application of Rehmannia glutinosa polysaccharide in the preparation of an anti-PRV preparation for the prevention and / or treatment of swine pseudorabies. This invention utilizes Rehmannia glutinosa polysaccharide to prevent infection by the PRV variant XJ5 by reducing intracellular oxidative stress levels; it also resists viral infection by affecting viral adsorption. Furthermore, when the concentration of Rehmannia glutinosa polysaccharide is between 50 and 400 μg / mL, it can also affect viral entry and replication, and has no cytotoxicity to PK-15 cells.

The invention discloses application of PD-L1 as a drug target for resisting pseudorabies virus infection, the invention discloses PD-L1 as a key host limiting factor for pseudorabies virus infection for the first time, and knockout of PD-L1 can significantly promote replication of pseudorabies virus and induce apoptosis and inflammatory response of host cells. And PD-L1 overexpression can effectively inhibit proliferation of the pseudorabies virus and induce apoptosis and inflammatory response of host cells. Mechanism research results show that PD-L1 can be combined with envelope proteins gB and gD of the pseudorabies virus, and the effect of resisting pseudorabies virus infection is achieved through a cGAS-STNG-IFN pathway. The further research finds that the 125th arginine (ARG125) and the 271th lysine (LYS271) of the PD-L1 protein play a key role in the anti-pseudorabies virus infection effect of the PD-L1. The invention provides a new target spot for drugs for preventing or treating pseudorabies virus infection, and has a good application prospect in the aspect of resisting pseudorabies virus.

The utility model relates to the technical field of farm disinfection, and disclose a pig pseudorabies prevention disinfection structure, including passageway frame, the upper surface fixed connection of passageway frame has the disinfection and killing main part mechanism, the output end fixed communication of disinfection and killing main part mechanism has the spray head, the outside of passageway frame is provided with non -contact disinfection mechanism, and non -contact disinfection mechanism includes two fixed frame, and the inside of every fixed frame all is provided with the shelter door pole. The pig pseudorabies prevention disinfection structure, through passageway frame, disinfection and killing main part mechanism, spray head, fixed frame, shelter door, button controller, warning light, warning device, first infrared distance sensor, second infrared distance sensor, servo motor and rotary lever, passageway frame can be installed at the pig house entrance and exit, and then when the breeding worker enters and exits passageway frame, first infrared distance sensor can monitor that personnel has stood in passageway frame, and second infrared distance sensor can monitor that there is no shelter at two shelter doors.

This study describes the construction, identification, and application of a pseudorabies virus (PRV) triple-gene deletion vaccine strain (gI / gE / TK). Based on the JS-2012-ΔgI / gE double-gene deletion strain, the TK virulence gene was further deleted using CRISPR technology. Its pathogenicity was evaluated in KM mice and piglets, and its immunoprotective efficacy was verified in piglets. This provides theoretical support for the clinical prevention and control of pseudorabies; establishes experimental models in mice and pigs to study the immunoprotective efficacy of the triple-gene deletion strain; and prepares for the subsequent development and evaluation of vaccines using PRV strains as vectors.

The invention belongs to the technical field of veterinary biological products, and particularly relates to a swine fever-porcine pseudorabies bivalent subunit vaccine containing a traditional Chinese medicine immunopotentiator as well as a preparation method and application of the swine fever-porcine pseudorabies bivalent subunit vaccine. The enhancer is prepared by compounding a hypericum perforatum extract and a horse chestnut seed extract, the hypericum perforatum extract and the horse chestnut seed extract are mixed with a classical swine fever virus (CSFV) E2 protein, a pseudorabies virus (PRV) gB protein, a PRV gD protein and an adjuvant to prepare a subunit vaccine, the vaccine can remarkably improve the humoral immunity level and the cellular immunity level excited by the vaccine at the same time, and the vaccine can be used for preparing the vaccine. Specifically, cell factors such as neutralizing antibodies GMT and IFN-gamma are remarkably increased, and the uniformity and stability of immune response are promoted, so that the immunogenicity of the existing swine fever-porcine pseudorabies bigeminy subunit vaccine is effectively improved, and the protection effect of the vaccine is enhanced.

The application discloses a recombinant pseudorabies virus strain expressing classical swine fever virus E2 protein and application, and relates to the technical field of biology.The recombinant E2 protein provided by the application successfully realizes high-level expression of the E2 protein by removing the transmembrane region of the E2 protein and using the 18aa signal peptide of the E2 protein itself and a pig albumin signal peptide.The recombinant PRV expressing the classical swine fever virus (CSFV) E2 protein can induce E2 antibodies and cellular immunity after immunization of mice.The recombinant pseudorabies virus strain provided by the application can be used as a bivalent vaccine for preventing CSFV and PRV infection.

This invention relates to the field of biomedical technology, specifically disclosing a STING agonist ST-71, its synthesis method, and its applications. ST-71 is obtained by modifying SR-717. The STING agonist ST-71 synthesized in this invention has the characteristics of good antiviral effect, low toxicity and side effects, and cost-effectiveness, and can also inhibit the proliferation of porcine pseudorabies virus.

The application discloses a reagent containing pig pseudorabies virus gB protein magnetic microparticle coating, a preparation method and a kit, and relates to the technical field of antibody detection. The preparation method of the reagent containing pig pseudorabies virus gB protein magnetic microparticle coating comprises the following steps: incubating magnetic microparticles and gB protein antibodies in a coating buffer solution; removing the reaction solution, and performing first sealing on the gB protein magnetic microparticle coating with a first sealing solution; after the first sealing is completed, the first sealing solution is washed away, and then the gB protein magnetic microparticle coating is sealed for the second time with a second sealing solution; after the second sealing is completed, the second sealing solution is washed away, and then resuspension is performed to obtain the reagent containing the gB protein magnetic microparticle coating. The two-step sealing method is adopted to prepare the reagent containing the pig pseudorabies virus gB protein magnetic microparticle coating, the sealing effect is good, and non-specific adsorption in the system is reduced. The kit provided by the application contains the reagent, and has the advantages of high analysis sensitivity, a wide linear range and high accuracy.

This invention relates to the field of biomedical technology, specifically to a stably expressed porcine pseudorabies virus gD recombinant protein, a vaccine composition, its preparation method, and its applications. The invention provides a stably expressed porcine pseudorabies virus gD recombinant protein, the amino acid sequence of which is shown in SEQ ID NO:7. The porcine pseudorabies virus gD recombinant protein is stably expressed in monoclonal cells, exhibiting stable expression levels after 48 consecutive passages. This lays a solid foundation for its subsequent applications in the preparation of stable porcine pseudorabies subunit vaccine compositions or in porcine pseudorabies virus vaccine efficacy testing formulations.

The application provides a construction and application of a recombinant pseudorabies virus strain stably and efficiently expressing green fluorescent protein, in the research, a green fluorescent protein gene (EGFP) is inserted into different positions of a double gene deletion vaccine strain (JS-2012-△gE / gI) of a pseudorabies virus mutant strain by using a homologous recombination method. Finally, it is proved that the recombinant virus JS-2012-△gE / gI-VP1 / 2-EGFP has good genetic stability, and the EGFP gene can also be stably and efficiently expressed, and the growth rate on cells is also comparable to that of the parent virus, so that the VP1 / 2 gene is the best exogenous gene insertion site. Subsequently, the classical swine fever virus E2 gene, the parvovirus VP2 gene, the cap gene of the circovirus type 2 and the VP1 gene of the foot-and-mouth disease virus can be replaced or inserted into the EGFP expression frame in a single or combined manner to construct different types of multi-vaccines, and the multi-vaccines have extremely high research value and platform significance.

This invention discloses monoclonal antibodies that recognize linear B-cell epitopes in the conserved extracellular domain of pseudorabies virus (PRV) gE protein and their applications. Using recombinant PRV gE protein extracellular domain protein as an immunogen, hybridoma cell lines were prepared. Combining dot blot and peptide scanning techniques, two monoclonal antibodies, 4E5D7 and 8F6B2, were screened to recognize the 69-93aa region of the conserved extracellular domain of the PRV gE protein. Both antibodies achieved a titer of 1:2048000 and specifically recognized the native PRV wild-type gE protein, showing no cross-reactivity with gE gene-deleted vaccines. The monoclonal antibodies of this invention fill the gap in detection reagents targeting the precise epitopes of the 69-81aa and 79-93aa extracellular domains of the PRV gE protein, thus improving the linear B-cell epitope map of the PRV gE protein. These monoclonal antibodies can be used for research on the pathogenesis of PRV and the development of specific detection reagents for PRV wild-type strains, possessing significant application value and translational prospects in basic scientific research, veterinary clinical testing, and animal disease prevention and control.

The invention belongs to the technical field of biological immunity, and particularly relates to a monoclonal antibody for resisting pseudorabies virus gC protein and application of the monoclonal antibody. The affinity of the anti-PRV monoclonal antibody is greater than or equal to 5 * 10 < 9 > L / mol, the ELISA titer is greater than or equal to 1: 5.12 * 10 < 5 >, the IPMA titer is 1: 6.4 * 10 < 3 >, and the anti-PRV monoclonal antibody has the characteristic of high sensitivity. And the kit is suitable for various detection platforms such as ELISA, IPMA, Western Blot and the like, and a reliable tool is provided for rapid detection of the PRV antigen.

This application relates to the technical field of pseudorabies virus detection, specifically to a primer combination for pseudorabies virus detection, its application, and a reagent kit. Specifically, the amplification primers in this application exhibit good specificity and amplification efficiency when used for pseudorabies virus detection, and demonstrate good linear regression performance, enabling more accurate and precise quantitative detection of pseudorabies virus.

The invention relates to the technical field of antibodies, and discloses an antibody for specifically recognizing porcine pseudorabies virus gB (59-337aa) or an antigen binding fragment thereof and application. The antibody or the antigen binding fragment thereof comprises a heavy chain and a light chain; the antibody or the antigen binding fragment thereof can be used for detecting the existence or the level of the porcine pseudorabies virus gB protein in a sample, and has key significance on optimization of a porcine pseudorabies virus detection method, improvement of diagnosis accuracy and realization of effective prevention and control of epidemic situations.

The invention discloses a composition containing a G4 stabilizer and a TLS pathway inhibitor and application of the composition. The G4 stabilizer is TMPyP4, the TLS pathway inhibitor is JH-RE-06, and the mass ratio of the G4 stabilizer to the TLS pathway inhibitor is (15-30): 1; the composition can be used for preparing drugs for preventing or treating pseudorabies virus infection or diseases related to pseudorabies virus infection, or can be used for preparing products for inhibiting replication and proliferation of pseudorabies virus or DNA synthesis. Therefore, the invention provides a novel antiviral strategy of blocking virus DNA synthesis through double targets instead of directly acting on virus protein, and provides a new drug research and development path and treatment thought for coping with PRV variants and breaking through the insufficient protection of existing vaccines.

The application belongs to the field of biological medicine and virus infection, and particularly relates to an inhibitor for limiting virus-mediated cell-cell fusion. The application specifically discloses an inhibitor for limiting cell-cell fusion mediated by pseudorabies virus (PRV), wherein the inhibitor contains MARCH1 protein, and the MARCH1 protein includes a derivative thereof, an isolated nucleic acid molecule, a vector or a host cell containing the MARCH1 protein, and / or a fusion. It is found in the research that MARCH1 significantly inhibits the replication of PRV in the stage of cell-cell fusion, that is, it is found in the application that MARCH1 captures a virus protein complex inducing cell-cell fusion in a trans-Golgi network (TGN), and it is proved that MARCH1 has anti-PRV infection activity.

The invention relates to the technical field of antibodies, and discloses an antibody for specifically recognizing porcine pseudorabies virus gE (52-260aa) or an antigen binding fragment thereof and application. The antibody or the antigen binding fragment thereof comprises a heavy chain and a light chain; the antibody can realize specific recognition on gE protein and is used for detecting a target antigen in a sample. The antibody can be used as a core reagent in an immunodetection system, is suitable for laboratory detection and on-site rapid screening of porcine pseudorabies, is beneficial to improving the monitoring efficiency of basic-level and large-scale breeding links, and provides a technical guarantee for early discovery and accurate prevention and control of epidemic situations. Meanwhile, the antibody can also be used as a research tool to be applied to research on gE protein related biological functions and effects of the gE protein in a virus pathopoiesis process, and important support is provided for clarification of virus variation characteristics and optimization of subsequent prevention and control and diagnosis strategies.

The invention relates to the technical field of biological detection, and discloses a primer probe group and a detection kit for simultaneously detecting three porcine pathogens. The invention firstly provides two primer probe groups for simultaneously detecting the porcine pseudorabies virus, the porcine cytomegalovirus and the porcine lymphotropic herpesvirus, one group is used for detecting the porcine lymphotropic herpesvirus type 1 and the porcine lymphotropic herpesvirus type 2, the other group is used for detecting the porcine lymphotropic herpesvirus type 2, and the other group is used for detecting the porcine lymphotropic herpesvirus type 3. And the other group of primers is used for detecting the swine lymphotropic herpesvirus type 3. Meanwhile, the invention also provides a detection kit containing the primer probe group. When being used for detection, the primer probe group has the advantages of high sensitivity, high specificity and simplicity in operation, can be used for simultaneously, quickly and accurately detecting the porcine pseudorabies virus, the porcine cytomegalovirus and the porcine lymphotropic herpesvirus type 1, the porcine cytomegalovirus type 2 and the porcine lymphotropic herpesvirus type 3, and provides an effective technical means for detecting and distinguishing the three viruses and subtypes in a laboratory.

The invention relates to a engineered pseudorabies virus (PRV) to express protective antigens derived from viruses associated with infection in swine. The PRV recombinant vector is a triple deletion mutant and includes a deletion in the gene encoding glycoprotein gE, a deletion in the gene encoding glycoprotein gG and a deletion in the gene encoding tyrosine kinase (TK), wherein at least one heterologous antigen is inserted in at least one deletion locus. The PRV recombinant vector can include at least three heterologous antigens inserted therein. Included are methods for creating recombinant vectors, mutant viruses, and vaccines for preventing or reducing symptoms associated with viral infection in swine, in particular classical swine fever (CSF) and Porcine circovirus type 2 (PCV2).

The invention provides a subunit vaccine composition for swine fever, porcine pseudorabies, porcine circovirus and swine erysipelas as well as a preparation method and application of the subunit vaccine composition. The subunit vaccine composition comprises prokaryotically expressed swine erysipelas filamentous bacillus SpaA protein, viral subunit protein and pharmaceutically acceptable adjuvants. Wherein the amino acid sequence of the prokaryotically expressed swine erysipelas filamentous bacillus SpaA protein is as shown in SEQ No.1, and the viral subunit protein is selected from one or more of subunit E2 protein of hog cholera virus, gD protein of porcine pseudorabies virus, gB protein of porcine pseudorabies virus and cap protein of porcine circovirus type 2. The vaccine composition disclosed by the invention has the advantages of strong immunogenicity, good safety, no immune interference, high neutralizing antibody titer and long antibody duration; the infection of swine erysipelas filamentous bacillus can be effectively prevented and protected.

The invention belongs to the technical field of animal disease prevention and control, and discloses application of a traditional Chinese medicine monomer perillyl alcohol in preparation of a medicine for preventing or treating porcine pseudorabies. According to the present invention, the influence of the perillyl alcohol with different concentrations on the activity of BHK-21 cells, the inhibition effect of the perillyl alcohol on the PRV on the BHK-21 cells, the inhibition effect of the perillyl alcohol on the PRV under different action modes, the protection effect of the perillyl alcohol on the PRV infection of mice, and the influence of the perillyl alcohol on inflammatory factors in the serum of the mice are determined; the effect of the perillyl alcohol in the process of inhibiting porcine pseudorabies virus infection is verified, the application value of the perillyl alcohol in resisting the porcine pseudorabies virus is explored, and a theoretical basis and practical guidance are provided for prevention and control of the PRV. Besides, the perillyl alcohol is a medicine with a natural source, has the advantages of safety, few side effects, low metabolic residue and no pollution, and has relatively good popularization and application values.

The invention discloses an application of fangchinoline alkali in preparation of anti-pseudorabies virus drugs, the fangchinoline alkali has no significant toxicity to cells in a concentration range of 0-5 [mu] M, and the fangchinoline alkali significantly reduces pseudorabies virus infection by inhibiting virus genome replication, protein synthesis and progeny virus titer in a concentration range of 2-4 [mu] M; the fangchinoline can be used as an effective component for developing the anti-pseudorabies virus medicine, and has the advantages of safety, few toxic and side effects, low medicine residue, no pollution and the like.

The invention relates to application of miR-145-5P in preparation of a medicine for preventing and / or treating PRV (pseudorabies virus) infection related diseases, and belongs to the field of biological medicines. The miR-145-5p is found to be a key differential expression molecule in the PRV infected piglet lung and colon tissue exosome through high-throughput sequencing for the first time. In-vitro cell experiments prove that up-regulation of the expression of the miR-145-5p can significantly play an antiviral role through double mechanisms of inhibiting PRV virus replication and promoting apoptosis of infected cells, and research results of the invention provide a brand new target and strategy for prevention and treatment of PRV.

The application belongs to the technical field of biology and particularly relates to a nucleic acid aptamer targeting African swine fever virus A104R protein and use thereof. First, the nucleic acid aptamer APT-1 capable of specifically combining with A104R protein is screened out by taking African swine fever virus A104R protein as a combination antigen, the nucleic acid aptamer is single-stranded DNA, and the nucleotide sequence is shown as SEQ ID NO. 1. Second, the nucleic acid aptamer APT-1 has good affinity and reactivity with African swine fever virus protein A104R and has no cross reaction with p30 protein, and has good specificity. The nucleic acid aptamer APT-1 is used for detecting African swine fever virus antibody, has high sensitivity and specificity, and has no cross reaction with porcine circovirus type 2, porcine reproductive and respiratory syndrome virus, porcine pseudorabies virus, porcine parvovirus, foot-and-mouth disease virus and swine fever virus.

The application belongs to the technical field of animal disease prevention and control, and discloses application of a traditional Chinese medicine monomer, i.e., a perillyl alcohol, in preparation of a medicine for preventing or treating a pseudorabies of pigs. The application verifies the role of the perillyl alcohol in inhibiting a pig pseudorabies virus infection process and explores the application value of the perillyl alcohol in resisting the pig pseudorabies virus, and provides a theoretical basis and practical guidance for prevention and control of the PRV. In addition, the perillyl alcohol is a natural source medicine, has the advantages of safety, few side effects, low metabolic residues and no pollution, and has good popularization and application value.

The present invention pertains to the technical field of biology and specifically relates to a recombinant oncolytic virus and use thereof. With a TK gene single-deletion virus strain as a backbone and the US3 and EP0 genes as "platforms", the recombinant oncolytic virus is obtained by inserting an immunomodulatory cytokine gene. Compared with the wild-type pseudorabies virus, the modified pseudorabies virus has enhanced replication efficiency in human tumor cells, an improved ability to induce pathological changes in human tumor cells, an improved ability to kill human tumor cells, and an enhanced ability to induce innate immune responses. The recombinant oncolytic virus can be used as a single agent or in combination with other anticancer drugs to enable the combined application of tumor immunotherapy. The present invention provides a wider field of view, more possibilities, and new hopes for tumor treatment, and also provides more effective and safer treatment options for patients.

The invention belongs to the technical field of genetic engineering, and particularly relates to a neutralizing monoclonal antibody of a pseudorabies virus gB protein and an antigen epitope peptide and application thereof. An escherichia coli expression system capable of stably expressing the PRV gB protein is designed and constructed, a mouse is immunized by taking the purified gB protein as an immunogen, and the monoclonal cell strain resisting the PRV gB protein is screened through an immunoperoxidase monolayer cell test (IPMA) by utilizing a cell fusion technology and taking the stably expressed gB protein as a detection antigen. The titer of the monoclonal antibody IPMA generated by the cell strain is 1: 32000, the neutralizing titer is 1: 24, the monoclonal antibody can specifically recognize and combine with a 615RVPGERGTC623 sequence region on the gB protein, the interaction between an antigen and the antibody can be known, the monoclonal antibody has important guiding significance on development of vaccines and detection reagents based on the gB protein, and a technical support is provided for prevention, control and treatment of PRV.

The application discloses a fluorescent PCR kit for detecting pseudorabies virus and application, the kit comprises a primer and probe combination for detecting the pseudorabies virus and a primer and probe combination of an internal standard, the nucleotide sequence of the upstream primer for detecting the pseudorabies virus is shown in SEQ ID NO: 7, the nucleotide sequence of the downstream primer is shown in SEQ ID NO: 8, and the nucleotide sequence of the probe is shown in SEQ ID NO: 9; the nucleotide sequence of the upstream primer of the primer and probe combination of the internal standard is shown in SEQ ID NO: 10, the nucleotide sequence of the downstream primer is shown in SEQ ID NO: 11, and the nucleotide sequence of the probe is shown in SEQ ID NO: 12. The minimum detection limit of the kit is 1.5*10 2 copies / mL, which is at least 10 times higher than that of a national standard method, the kit has excellent specificity, and is helpful to realize rapid diagnosis and early prevention and control and reduce the risk of epidemic spread.